Schultz issues detail on post-market clinical trials
This article was originally published in Clinica
Executive Summary
The FDA's new series of initiatives aimed at ensuring that companies actually perform their post-market clinical trials conducted as a condition of approval will not have any effect on pre-2005 studies, the director of the agency's device centre told Clinica this week.